Alligator Bioscience AB (publ) Interim report January-March 2020
Stronger focus on clinical projects "The focusing of our operations protects the company’s liquidity, but is also part of our long-term ...
Alligator Bioscience AB Year-end Report January-December 2019
"2019 was the year when Alligator entered the clinical phase on a broad front. At the beginning of the year, we had one clinical project ...
Alligator Bioscience AB Interim report January-September 2019
"We are now regaining the exclusive, global rights to develop and commercialize ADC-1013 and at the same time receive enough ADC-1013 su ...
Alligator Bioscience AB (publ) Interim report January-June 2019
Competitive safety data for ADC-1013. Significant events April-June• Janssen presented data from the clinical Phase I study with ADC-1013 in ...
Alligator Bioscience AB (publ) Interim report January-March 2019
First patient dosed in Phase I clinical study of ATOR-1015 Significant events January-March• First patient dosed in Phase I clinical study o ...
Alligator Bioscience AB Year-end Report 2018
The bispecific drug candidate ATOR-1015 in clinical development Significant events October-December• The Swedish MPA (Medical Products Agenc ...
Alligator Bioscience AB Interim Report January-September 2018
The science behind the Nobel Prizes in Medicine and Chemistry constitutes the core in Alligator’s research and development. Significant even ...
Alligator Bioscience AB Interim Report January-June 2018
Positive data for our preclinical projects Significant events April-June• The ADC-1013 clinical phase I study performed by Janssen is ongoin ...
Alligator Bioscience AB Interim Report January-March 2018
Positive preclinical data for ATOR-1015 "Data provide strong support for our claims that ATOR-1015 is a next generation bispecific CTLA- ...